Nymox Pharmaceutical Corporation NYMX

$ 0.2 -19.68%

Annual report 2022
added 12-21-2024

Nymox Pharmaceutical Corporation Balance Sheet 2011-2024 | NYMX

Annual Balance Sheet Nymox Pharmaceutical Corporation

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-7.95 M	-851 K	-1.09 M	440 K	86.6 K	-296 K	-1.03 M	-5.92 M
Long Term Debt	-	-	-	-	-	-	931 K	815 K	719 K	-	-	-
Long Term Debt Current	-	-	-	-	23 K	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	368 K	3 K	-	-	1.33 M	1.21 M	1.12 M	2.91 M	5.53 M	8.14 M
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	2.11 M	1.95 M	2.2 M	2.04 M	1.07 M	2.23 M	2.7 M	3.47 M	5.6 M	7.02 M	9.2 M	11.6 M
Deferred Revenue	-	-	-	-	-	-	-	-	2.51 M	2.62 M	2.62 M	2.62 M
Retained Earnings	-	-193 M	-180 M	-168 M	-155 M	-145 M	-131 M	-118 M	-100 M	-95.1 M	-89.9 M	-82.1 M
Total Assets	1.62 M	1.44 M	4.34 M	5.49 M	8.08 M	979 K	2.06 M	712 K	1.42 M	966 K	1.75 M	6.38 M
Cash and Cash Equivalents	-	830 K	3.61 M	5.24 M	7.95 M	851 K	2.02 M	374 K	-	-	-	-
Book Value	-482 K	-506 K	2.14 M	3.45 M	7 M	-1.25 M	-641 K	-2.75 M	-4.18 M	-6.06 M	-7.44 M	-5.2 M
Total Shareholders Equity	-	-506 K	2.14 M	3.45 M	7 M	-1.25 M	-241 K	-2.35 M	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Nymox Pharmaceutical Corporation

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	108 K	163 K	-	-	-	-	-	-	-	-	-	238 K	281 K	319 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	2.63 M	1.95 M	2.27 M	1.96 M	1.47 M	2.2 M	1.9 M	2.12 M	1.93 M	2.04 M	1.81 M	1.95 M	1.71 M	1.07 M	849 K	1.62 M	2 M	2.23 M	-	-	-	2.3 M	-	-	-	3.06 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-198 M	-193 M	-190 M	-186 M	-182 M	-180 M	-178 M	-174 M	-171 M	-168 M	-166 M	-163 M	-158 M	-155 M	-152 M	-150 M	-147 M	-145 M	-	-	-	-131 M	-	-	-	-118 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	1.24 M	1.44 M	3.85 M	6.67 M	1.46 M	4.34 M	5.74 M	1.06 M	3.37 M	5.49 M	7.46 M	9.52 M	11.8 M	8.08 M	4.78 M	5.17 M	954 K	979 K	-	-	-	2.06 M	-	-	-	712 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	672 K	830 K	3.14 M	6.2 M	880 K	3.61 M	5.36 M	767 K	3 M	5.24 M	7.14 M	9.1 M	11.3 M	7.95 M	4.66 M	5.04 M	850 K	851 K	1.74 M	1.26 M	1.63 M	2.02 M	-	-	-	374 K	-	-	-	632 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-1.39 M	-506 K	1.58 M	4.71 M	-12 K	2.14 M	3.84 M	-1.06 M	1.44 M	3.45 M	5.65 M	7.56 M	10.1 M	7 M	3.93 M	3.55 M	-1.04 M	-1.25 M	-	-	-	-242 K	-	-	-	-2.35 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-1.39 M	-506 K	1.58 M	4.71 M	-12 K	2.14 M	38.4 M	-1.06 M	1.44 M	3.45 M	5.65 M	7.56 M	10.1 M	7 M	3.93 M	3.55 M	-1.04 M	-1.25 M	-	-	-	-241 K	-	-	-	-2.35 M	-	-	-	-3.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency